Literature DB >> 10683188

Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine.

A A Coutts1, N Brewster, T Ingram, R K Razdan, R G Pertwee.   

Abstract

The controversial nature of the CB(1) receptor antagonist, SR141716A, in the guinea-pig small intestine was investigated by comparing it with four analogues of Delta(8)-tetrahydrocannabinol (Delta(8)-THC): O-1184, O-1238, O-584 and O-1315. These compounds (10 - 1000 nM) inhibited the electrically-evoked contractions with a rank order of potency of O-1238>O-1184>O-584>O-1315. Log concentration-response curves for O-1238, O-1184 and O-1315 were significantly shifted to the right by SR141716A and the maxima were significantly less than that of the CB(1) agonist, WIN55212-2, an indication of partial agonism. Partial saturation of the triple bond in O-1184 to a cis double bond (O-1238) increased its potency as an agonist (pEC(50) from 6.42 to 7.63) and as an antagonist of WIN55212-2, (pK(B), from 8.36 to 9.49). Substitution of the terminal azide group by an ethyl group (O-584) or removal of the phenolic hydroxyl group (O-1315) had no significant effect on the agonist or antagonist potency. None of these analogues increased the twitch response in a manner resembling that of SR141716A. O-1184 (10 and 100 nM) shifted the log concentration-response curve of WIN55212-2 for inhibition of the twitch responses to the right with pK(B) values of 8.29 and 8.38, respectively. We conclude that these Delta(8)-THC analogues behave as partial agonists rather than silent antagonists at CB(1) binding sites in this tissue. There was no evidence of antagonism of endocannabinoids thus supporting the hypothesis that, in this tissue, SR141716A is an inverse agonist of constitutively active CB(1) receptors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10683188      PMCID: PMC1571886          DOI: 10.1038/sj.bjp.0703094

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  SR 141716A, a cannabinoid receptor antagonist, produces hyperalgesia in untreated mice.

Authors:  J D Richardson; L Aanonsen; K M Hargreaves
Journal:  Eur J Pharmacol       Date:  1997-01-29       Impact factor: 4.432

2.  Cannabinoid-precipitated withdrawal: a time-course study of the behavioral aspect and its correlation with cannabinoid receptors and G protein expression.

Authors:  T Rubino; G Patrini; P Massi; D Fuzio; D Viganò; G Giagnoni; D Parolaro
Journal:  J Pharmacol Exp Ther       Date:  1998-05       Impact factor: 4.030

3.  SR141716A is an inverse agonist at the human cannabinoid CB1 receptor.

Authors:  R S Landsman; T H Burkey; P Consroe; W R Roeske; H I Yamamura
Journal:  Eur J Pharmacol       Date:  1997-09-03       Impact factor: 4.432

4.  Cannabinoid modulation of intestinal propulsion in mice.

Authors:  G Colombo; R Agabio; C Lobina; R Reali; G L Gessa
Journal:  Eur J Pharmacol       Date:  1998-02-26       Impact factor: 4.432

5.  Arousal-enhancing properties of the CB1 cannabinoid receptor antagonist SR 141716A in rats as assessed by electroencephalographic spectral and sleep-waking cycle analysis.

Authors:  V Santucci; J J Storme; P Soubrié; G Le Fur
Journal:  Life Sci       Date:  1996       Impact factor: 5.037

6.  Evidence for the presence of cannabinoid CB1 receptors in mouse urinary bladder.

Authors:  R G Pertwee; S R Fernando
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

7.  Further evidence for the presence of cannabinoid CB1 receptors in guinea-pig small intestine.

Authors:  R G Pertwee; S R Fernando; J E Nash; A A Coutts
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

8.  Inhibition by cannabinoid receptor agonists of acetylcholine release from the guinea-pig myenteric plexus.

Authors:  A A Coutts; R G Pertwee
Journal:  Br J Pharmacol       Date:  1997-08       Impact factor: 8.739

9.  A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.

Authors:  M Bouaboula; S Perrachon; L Milligan; X Canat; M Rinaldi-Carmona; M Portier; F Barth; B Calandra; F Pecceu; J Lupker; J P Maffrand; G Le Fur; P Casellas
Journal:  J Biol Chem       Date:  1997-08-29       Impact factor: 5.157

10.  Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors.

Authors:  R Mechoulam; S Ben-Shabat; L Hanus; M Ligumsky; N E Kaminski; A R Schatz; A Gopher; S Almog; B R Martin; D R Compton
Journal:  Biochem Pharmacol       Date:  1995-06-29       Impact factor: 5.858

View more
  10 in total

1.  Pharmacological analysis of cannabinoid receptor activity in the rat vas deferens.

Authors:  A Christopoulos; P Coles; L Lay; M J Lew; J A Angus
Journal:  Br J Pharmacol       Date:  2001-03       Impact factor: 8.739

2.  Agonist-induced internalization and trafficking of cannabinoid CB1 receptors in hippocampal neurons.

Authors:  A A Coutts; S Anavi-Goffer; R A Ross; D J MacEwan; K Mackie; R G Pertwee; A J Irving
Journal:  J Neurosci       Date:  2001-04-01       Impact factor: 6.167

3.  Structural domains of the CB1 cannabinoid receptor that contribute to constitutive activity and G-protein sequestration.

Authors:  J Nie; D L Lewis
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 4.  Cannabinoids and the gastrointestinal tract.

Authors:  R G Pertwee
Journal:  Gut       Date:  2001-06       Impact factor: 23.059

Review 5.  Cannabinoid receptors: nomenclature and pharmacological principles.

Authors:  Linda Console-Bram; Jahan Marcu; Mary E Abood
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2012-02-28       Impact factor: 5.067

6.  Structural and pharmacological analysis of O-2050, a putative neutral cannabinoid CB(1) receptor antagonist.

Authors:  Jenny L Wiley; Christopher S Breivogel; Anu Mahadevan; Roger G Pertwee; Maria Grazia Cascio; Daniele Bolognini; John W Huffman; D Matthew Walentiny; Robert E Vann; Raj K Razdan; Billy R Martin
Journal:  Eur J Pharmacol       Date:  2010-11-27       Impact factor: 4.432

7.  The effect of anandamide on uterine nitric oxide synthase activity depends on the presence of the blastocyst.

Authors:  Micaela S Sordelli; Jimena S Beltrame; Juliana Burdet; Elsa Zotta; Romina Pardo; Maximiliano Cella; Ana M Franchi; Maria Laura Ribeiro
Journal:  PLoS One       Date:  2011-04-29       Impact factor: 3.240

8.  Endocannabinoids in the Gut.

Authors:  Nicholas V DiPatrizio
Journal:  Cannabis Cannabinoid Res       Date:  2016-02-24

9.  The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation.

Authors:  Eric W Bow; John M Rimoldi
Journal:  Perspect Medicin Chem       Date:  2016-06-28

10.  Rimonabant, gastrointestinal motility and obesity.

Authors:  Yan Sun; Jiande Dz Chen
Journal:  Curr Neuropharmacol       Date:  2012-09       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.